Detalle Publicación

ARTÍCULO

Myocyte enhancer factor 2D promotes colorectal cancer angiogenesis downstream of hypoxia-inducible factor 1 alpha

Autores: Xiang, J. Y.; Sun, H.; Su, L.; Liu, L. M.; Shan, J. J.; Shen, J. J.; Yang, Z.; Chen, J.; Zhong, X.; Ávila Zaragoza, Matías Antonio; Yan, X. C.; Liu, C. G.; Qian, C.
Título de la revista: CANCER LETTERS
ISSN: 0304-3835
Volumen: 400
Páginas: 117 - 126
Fecha de publicación: 2017
Resumen:
Myocyte enhancer factor 2D (MEF2D) is involved in many aspects of cancer progression, including cell proliferation, invasion, and migration. However, little is known about the role of MEF2D in tumor angiogenesis. Using clinical specimens, colorectal cancer (CRC) cell lines and a mouse model in the present study, we found that MEF2D expression was positively correlated with CD31-positive micro-vascular density in CRC tissues. MEF2D promoted tumor angiogenesis in vitro and in vivo and induced the expression of proangiogenic cytokines in CRC cells. MEF2D was found to be a downstream effector of hypoxia-inducible factor (HIF)-1 alpha in the induction of tumor angiogenesis. HIF-1 alpha transactivates MEF2D expression by binding to the MEF2D gene promoter. These results demonstrate that the HIF-1 alpha/MEF2D axis can serve as a therapeutic target for the treatment of CRC. (C) 2017 Elsevier B.V. All rights reserved.
DOI: https://doi.org/10.1016/j.canlet.2017.04.037
Impacto:
27 citas en
Google Scholar